Prevalence and clustering of metabolic risk factors for type 2 diabetes among Chinese adults in Shanghai, China

He Xu; Yiqing Song; Nai-Chieh You; Zuo-Feng Zhang; Greenland, Sander; Ford, Earl S.; Lin He; Simin Liu
January 2010
BMC Public Health;2010, Vol. 10 Issue 1, p683
Academic Journal
Background: Type 2 diabetes is becoming an epidemic in China. To evaluate the prevalence, clustering of metabolic risk factors and their impact on type 2 diabetes, we conducted a population-based study in Shanghai, China's largest metropolitan area. Methods: From 2006 to 2007, 2,113 type 2 diabetes cases and 2,458 comparable controls of adults aged 40 to 79 years were enrolled. Demographic, lifestyle, and dietary factors were assessed via standardized questionnaires. Plasma, red and white blood cells were collected and stored for future studies. Anthropometric indices and biochemical intermediates (including blood pressure, fasting glucose, glycosylated hemoglobin, and blood lipids) were measured. The prevalence of metabolic syndrome were also compared following two criteria recommended by the Chinese Diabetes Society (CDS, 2004) and the National Cholesterol Education Program's Adult Treatment Panel III (ATP III, 2002). Results: Prevalence of metabolic syndrome (62% vs. 15% using CDS criteria) and its individual components, including obesity (51% vs. 42%), hypertension (54% vs. 41%), hypertriglyceridemia (42% vs. 32%), and low high-density lipoprotein-cholesterol (HDL) levels (36% vs. 25%) were higher in diabetes cases than controls. Regardless of criteria used, those with impaired fasting glucose (IFG) had similarly high prevalence of metabolic syndrome as did diabetes cases. In a multiple logistic regression model adjusted for demographics and lifestyle risk factors, the odds ratios of diabetes (95% CI) were 1.23 (1.04-1.45) for overweight (28 >= BMI >= 24), 1.81 (1.45-2.25) for obesity (BMI > 28), 1.53 (1.30-1.80) for central obesity (waist circumference > 80 cm for woman or waist circumference > 85 cm for man), 1.36 (1.17-1.59) for hypertension (sbp/dbp >= 140/90 mmHg), 1.55 (1.32-1.82) for high triglycerides (triglycerides > 1.70 mmol/l) and 1.52 (1.23-1.79) for low HDL-C (HDL-C < 1.04 mmol/L). Conclusions: These data indicate that multiple metabolic risk factors-individually or jointly-were more prevalent in diabetes patients than in controls. Further research will examine hypotheses concerning the high prevalence of IFG, family history, and central obesity, aiding development of multifaceted preventive strategies specific to this population.


Related Articles

  • Relationship between body-roundness index and metabolic syndrome in type 2 diabetes. Liu, Bowei; Liu, Bo; Wu, Guangfei; Yin, Fuzai // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Jun2019, Vol. 12, p931 

    Background: The present study evaluated the relationship between body-roundness index (BRI) and metabolic syndrome (MetS) in type 2 diabetes. Methods: A cross-sectional study was conducted on 585 type 2 diabetes in Qinhuangdao. MetS was defined as per the Chinese Diabetes Society. Results: The...

  • Preventing Type 2 Diabetes. Harwell, Todd S.; Dettori, Nancy; Flook, Benjamin N.; Priest, Linda; Williamson, David F.; Helgerson, Steven D.; Gohdes, Dorothy // Diabetes Care;Nov2001, Vol. 24 Issue 11, p2007 

    Focuses on the results of a survey on the perceptions of Montana residents of the risk and prevention of type 2 diabetes. Subjects; Analyses of the results.

  • Serum butyrylcholinesterase in type 2 diabetes mellitus: a biochemical and bioinformatics approach. Sridhar, G. R.; Nirmala, G.; Apparao, Allam; Madhavi, A. S.; Sreelatha, S.; Rani, J. Sudha; Vijayalakshmi, P. // Lipids in Health & Disease;2005, Vol. 4, p18 

    Background: Butyrylcholinesterase is an enzyme that may serve as a marker of metabolic syndrome. We (a) measured its level in persons with diabetes mellitus, (b) constructed a family tree of the enzyme using nucleotide sequences downloaded from NCBI. Butyrylcholinesterase was estimated...

  • Metabolic Syndrome in Type 2 Diabetes Mellitus in Isfahan, Iran Prevalence and Risk Factors. Mohsen Janghorbani; Masoud Amini // Metabolic Syndrome & Related Disorders;Sep2007, Vol. 5 Issue 3, p243 

    Background Our goal was to estimate the prevalence and risk factors of metabolic syndrome (MetSyn) in people with type 2 diabetes mellitus (T2DM) using routinely collected data from a clinical information system at Isfahan Endocrinology and Metabolism Research Centre, Iran.Methods Consecutive...

  • Testosterone Replacement in Diabetes and the Metabolic Syndrome.  // OB/GYN Clinical Alert;Jun2011 Clinical Brief, p12 

    The article presents a study which determines the effects of testosterone (TST) two percent gel when applied in hypogonadal men with type 2 diabetes (DM2) or metabolic syndrome (MBS) who underwent treatment for one year.

  • Testosterone Replacement in Diabetes and the Metabolic Syndrome. Kuritzky, Louis // Neurology Alert;Jun2011 Clinical Brief, p12 

    The article presents a study conducted by a team led by T. H. Jones and published in the "Diabetes Journal" that explored testosterone (TST) replacement in type 2 diabetes (DM2) and metabolic syndrome (MBS).

  • Testosterone Replacement in Diabetes and the Metabolic Syndrome. Jones, T. H. // Internal Medicine Alert;5/29/2011 Supplement, p80 

    The article focuses on the study conducted by T. H. Jones regarding the effects of testosterone (TST) 2% gel daily applications in hypogonadal men with type 2 diabetes (DM2) and metabolic syndrome (MBS).

  • Human resistin and the RELM of Inflammation in diabesity. Al Hannan, Fatima; Culligan, Kevin Gerard // Diabetology & Metabolic Syndrome;2015, Vol. 7 Issue 1, p1 

    The initial discovery of resistin and resistin-like molecules (RELMs) in rodents suggested a role for these adipocytokines in molecular linkage of obesity, Type 2 Diabetes mellitus and metabolic syndrome. Since then, it became apparent that the story of resistin and RELMs was very much of mice...

  • Natural Products for the Treatment of Obesity, Metabolic Syndrome, and Type 2 Diabetes 2014. Thounaojam, Menaka C.; Nammi, Srinivas; Jadeja, Ravirajsinh // Evidence-based Complementary & Alternative Medicine (eCAM);2015, p1 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics